Saturday 17 October 2026
Export LYRA’s income statement to Excel — free account
Lyra Therapeutics, Inc.
LYRA Healthcare Biotechnology
Lyra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $398,000.00, down 74.1% from fiscal 2024. In the quarter to December 2025, revenue fell 96.7%, EPS grew 53.0% and free cash flow grew 45.4%, each against the same quarter a year earlier.
0.19
0.00
0.00%
Follow LYRA
Lyra Therapeutics, Inc. (LYRA) P/E ratio
Lyra Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| 14 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CRIS Curis, Inc. compare | n/m |
| BBLG Bone Biologics Corp. compare | n/m |
| ZVSA ZyVersa Therapeutics, Inc. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| ATXI Avenue Therapeutics, Inc. compare | n/m |
| LYRA Lyra Therapeutics, Inc. | n/m |
| MNTRQ 9 Meters Biopharma, Inc. compare | n/m |
| BTTX Better Therapeutics, Inc. compare | n/m |
| SEELQ Seelos Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)